Seminars in Nephrology
Volume 24, Issue 3 , Pages 269-286 , May 2004

Pediatric IgA nephropathies: clinical aspects and therapeutic approaches

  • Noel M Delos Santos

      Affiliations

    • Children’s Foundation Research Center at the Le Bonheur Children’s Medical Center and the Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN, USA
    • ,
  • Robert J Wyatt

      Affiliations

    • Children’s Foundation Research Center at the Le Bonheur Children’s Medical Center and the Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN, USA
    • Corresponding Author InformationAddress reprint requests to Robert J. Wyatt, MD, MS, Room 301 WPT, Children’s Foundation Research Center, 50 North Dunlap, Memphis, TN 38103, USA

References 

  1. D’Amico G. The commonest glomerulonephritis in the world (IgA nephropathy). Q J Med. 1987;64:709–727
  2. Utsunomiya Y, Kado T, Koda T, et al.  Features of IgA nephropathy in preschool children. Clin Nephrol. 2000;54:443–448
  3. Yoshikawa N, Tanaka R, Iijima K. Pathophysiology and treatment of IgA nephropathy in children. Pediatr Nephrol. 2001;16:446–457
  4. Cho BS, Kim SD, Choi YM, et al.  School urinalysis screening in Korea (Prevalence of chronic renal disease). Pediatr Nephrol. 2001;16:1126–1128
  5. Wyatt RJ, Julian BA, Baehler RW, et al.  Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994. J Am Soc Nephrol. 1998;9:853–858
  6. Clarkson AR. IgA nephropathy (History, classification, and geographical distribution). In:  Clarkson AR editors. IgA Nephropathy. Boston: Martinus Nijhoff; 1987;p. 1–8
  7. Jennette JC, Wall SD, Wilkman AS. Low incidence of IgA nephropathy in blacks. Kidney Int. 1985;28:944–950
  8. Seedat YK, Nathoo BC, Parag KB, et al.  IgA nephropathy in blacks and Indians of Natal. Nephron. 1988;50:137–141
  9. Oviasu E. IgA nephropathy (IgAN) presenting with the nephritic syndrome. Trop Geogr Med. 1992;44:365–368
  10. Sehic AM, Gaber LW, Roy S, et al.  Increased recognition of IgA nephropathy in African-American children. Pediatr Nephrol. 1997;11:435–437
  11. Utsunomiya Y, Koda T, Kado T, et al.  Incidence of pediatric IgA nephropathy. Pediatr Nephrol. 2003;18:511–515
  12. Berger J. IgA glomerular deposits in renal disease. Transplant Proc. 1968;1:939–944
  13. Levy M, Beaufils H, Gubler MC, et al.  Idiopathic recurrent macroscopic hematuria and mesangial IgA-IgG deposits in children (Berger’s disease). Clin Nephrol. 1973;1:63–69
  14. Wyatt RJ, Julian BA, Bhathena DB, et al.  IgA nephropathy (Presentation, clinical course and prognosis in children and adults). Am J Kidney Dis. 1984;4:192–200
  15. Kher KK, Makker SP, Moorthy B. IgA nephropathy (Berger’s disease)—A clinicopathologic study in children. Int J Pediatr Nephrol. 1983;4:11–18
  16. Levy M, Gonzalez-Burchard G, Broyer M, et al.  Berger’s disease in children. Medicine. 1985;64:157–180
  17. Berg UB. Long-term follow up of renal function in IgA nephropathy. Arch Dis Child. 1991;66:588–592
  18. Southwest Pediatric Nephrology Study Group . A multicenter study of IgA nephropathy in children. Kidney Int. 1982;22:643–652
  19. Hogg RJ, Silva FG, Wyatt RJ, et al.  Prognostic indicators in children with IgA nephropathy (Report of the Southwest Pediatric Nephrology Study Group). Pediatr Nephrol. 1994;8:15–20
  20. Wyatt RJ, Kritchevsky SB, Woodford SY, et al.  IgA nephropathy (Long-term prognosis for pediatric patients). J Pediatr. 1995;127:913–919
  21. Kitajima T, Murakami M, Sakai O. Clinicopathological features in Japanese patients with IgA nephropathy. Jpn J Med. 1983;22:219–222
  22. Kusomoto Y, Takebayashi S, Taguchi T, et al.  Long-term prognosis and prognostic indices of IgA nephropathy in juvenile and adult Japanese. Clin Nephrol. 1987;28:118–124
  23. Yoshikawa N, Ito H, Yoshiara S, et al.  Clinical course of immunoglobulin A nephropathy in children. J Pediatr. 1987;110:555–560
  24. Yoshikawa N, Ito H, Nakamura H. IgA nephropathy in children from Japan. Child Nephrol Urol. 1989;9:191–199
  25. Yoshikawa N, Ito H, Nakamura H. Prognostic indicators in childhood IgA nephropathy. Nephron. 1992;60:60–67
  26. Hisano S, Kawano M, Kaku Y, et al.  The natural history of screening detected IgA glomerulonephritis in children. Acta Pediatr Scand. 1991;80:1044–1050
  27. Stapleton FB, Roy S, Noe HN, Jerkins G. Hypercalciuria in children with hematuria. N Engl J Med. 1984;310:1345–1348
  28. Tasic V, Korneti P, Ristoska-Bojkovska , et al.  Idiopathic hypercalciuria preceding IgA nephritis in a child with recurrent hematuria. Pediatr Nephrol. 2003;18:394–396
  29. Southwest Pediatric Nephrology Study Group . Association of IgA nephropathy with steroid-responsive nephrotic syndrome. Am J Kidney Dis. 1985;5:157–164
  30. Wyatt RJ, Hogg RJ. Evidence-based assessment of treatment options for children with IgA nephropathies. Pediatr Nephrol. 2001;16:156–167
  31. Task Force on Blood Pressure Control in Children National Heart, Lung, and Blood Institute . Report of the Second Task Force on Blood Pressure Control in Children. Pediatrics. 1976;58:259–263
  32. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents . Update on the 1987 task force report on high blood pressure in children and adolescents (A working group report from the National High Blood Pressure Education Program). Pediatrics. 1998;98:649–658
  33. Delos Santos NM, Ault BH, Gharavi AG, et al.  Angiotensin-converting enzyme genotype and outcome in pediatric IgA nephropathy. Pediatr Nephrol. 2002;17:496–502
  34. Welch TR, McAdams J, Berry A. Rapidly progressive IgA nephropathy. Am J Dis Child. 1988;142:789–793
  35. Radford MG, Donadio JV, Bergstrahl EJ, et al.  Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol. 1997;8:199–207
  36. Haas M. Histological subclassification of IgA nephropathy (A clinicopathologic study of 244 cases). Am J Kidney Dis. 1997;29:829–842
  37. McEnery PT, McAdams AJ, West CD. Glomerular morphology, natural history and treatment of children with IgA-IgG mesangial nephropathy. In:  Kincaid-Smith P,  Mathew TH,  Becker EL editor. Glomerulonephritis (Natural History and Treatment). New York: Wiley; 1972;p. 305–320
  38. Michalk D, Waldherr R, Seelig HP, et al.  Idiopathic mesangial IgA-glomerulonephritis in childhood (Description of 19 pediatric cases and review of the literature). Eur J Pediatr. 1980;134:13–22
  39. Linne T, Aperia A, Broberger O, et al.  Course of renal function in IgA glomerulonephritis in children and adolescents. Acta Paediatr Scand. 1982;71:735–743
  40. Ariceta G, Gallego N, Lopez-Fernandez Y, et al.  Long-term prognosis of childhood IgA nephropathy in adult life. Med Clin (Barc). 2001;116:361–364
  41. D’Amico G. Natural history of idiopathic IgA nephropathy (Role of clinical and histologic prognostic factors). Am J Kidney Dis. 2000;36:227–237
  42. Beukhof JR, Ockhuizen T, Halie LM, et al.  Subentities within adult primary IgA-nephropathy. Clin Nephrol. 1984;22:195–199
  43. Zidar N, Cavic MA, Kenda RB, et al.  Effect of intrauterine growth retardation on the clinical course and prognosis of IgA glomerulonephritis in children. Nephron. 1998;79:28–32
  44. Lee SMK, Rao VM, Franklin WA, et al.  IgA nephropathy (Morphologic predictors of progressive disease). Hum Pathol. 1987;13:314–322
  45. Wyatt RJ, Emancipator SN, Kon V, et al.  IgA nephropathy Databank (Development of a system for management of renal biopsy acquired data). Am J Kidney Dis. 1997;6:817–828
  46. Andreoli SP, Yum MN, Bergstein JM. IgA nephropathy in children (Significance of glomerular basement membrane deposition of IgA). Am J Nephrol. 1986;6:28–33
  47. Yoshikawa N, Ito H, Yoshiya K, et al.  Henoch-Schönlein nephritis and IgA nephropathy in children (A comparison of clinical course). Clin Nephrol. 1987;27:233–237
  48. Toth T, Takebayashi S. Glomerular hypertrophy as a prognostic marker in childhood IgA nephropathy. Nephron. 1998;80:285–291
  49. Watanabe T, Kawachi H, Ikezumi Y, et al.  Glomerular CD8+ cells predict progression of childhood IgA nephropathy. Pediatr Nephrol. 2001;16:561–567
  50. Nagata M, Akioka Y, Tsunoda Y, et al.  Macrophages in childhood IgA nephropathy. Kidney Int. 1995;48:527–535
  51. Schena FP, D’Altri C, Cerullo G, et al.  ACE gene polymorphism and IgA nephropathy (An ethnically homogeneous study and meta-analysis). Kidney Int. 2001;60:732–740
  52. Rigat B, Hubert C, Alhenc-Gelas F, et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343–1346
  53. Tanaka R, Iijima K, Murakami R, et al.  ACE gene polymorphism in childhood IgA (Association with clinicopathologic findings). Am J Kidney Dis. 1998;31:774–779
  54. Asano T, Tatsuma N, Yoshida J, et al.  Association of angiotensin-converting enzyme gene polymorphism and renal pathology in Japanese children with IgA nephropathy. Clin Nephrol. 1999;51:335–340
  55. Maruyama K, Yoshida M, Nishio H, et al.  Polymorphisms of renin-angiotensin system genes in childhood IgA nephropathy. Pediatr Nephrol. 2001;16:350–355
  56. Shimomura M, Yoshikawa N, Iijima K, et al.  Polymorphism of immunoglobulin heavy chain switch region gene in children with severe IgA nephropathy. Clin Nephrol. 1995;43:211–215
  57. Tanaka R, Iijima K, Xu H, et al.  Role of platelet-activating factor acetylhydrolase gene mutation in Japanese childhood IgA nephropathy. Am J Kidney Dis. 1999;34:289–295
  58. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1989;95:2S–4S
  59. Rodicio JL, Alcazar JM, Ruilope LM. Influence of converting enzyme inhibition on glomerular filtration rate and proteinuria. Kidney Int. 1990;38:590–594
  60. Heeg JA, de Jong PE, van der Hem GK, et al.  Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int. 1987;32:78–84
  61. Remuzzi A, Perico N, Sangalli F, et al.  ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol. 1999;276:F457–F466
  62. Nolin L, Courteau M. Management of IgA nephropathy (Evidence-based recommendations). Kidney Int. 1999;70:S56–S62
  63. Floege J. Evidence-based recommendations for immunosuppression in IgA nephropathy (Handle with caution). Nephrol Dial Transplant. 2003;18:241–245
  64. Hebert LE, Wilmer WA, Falkenhain ME, et al.  Renoprotection (One or many therapies?). Kidney Int. 2001;59:1211–1223
  65. Glassock RJ. Treatment of IgA nephropathy (Status at the end of the millennium). J Nephrol. 1999;12:288–296
  66. Julian BA. Treatment of IgA nephropathy. Sem Nephrol. 2000;20:277–285
  67. Bhattacharjee R, Filler G. Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy. Pediatr Nephrol. 2002;17:302–304
  68. Hogg RJ, Wyatt RJ: A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy. (submitted)
  69. Coppo R, Chiesa M, Peruzzi L, et al.  Treatment of IgA nephropathy with angiotensin converting enzyme inhibitors (Design of a prospective randomized multicenter trial). J Nephrol. 2001;14:447–452
  70. Itami N, Akutsu Y, Kusunoki Y, et al.  Does methylprednisolone pulse therapy deteriorate the course if rapidly progressive IgA nephropathy?. Am J Dis Child. 1989;143:441–442
  71. Boobes Y, Baz M, Durand C, et al.  Early start of intensive therapy in malignant form of IgA nephropathy. Nephron. 1990;54:351–353
  72. Niaudet P, Murcia I, Beaufils H, et al.  Primary IgA nephropathies in children (Prognosis and treatment). Adv Nephrol. 1993;22:121–140
  73. Rocacatello D, Ferro M, Coppo R, et al.  Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy. Nephrol Dial Transplant. 1995;10:2054–2059
  74. Waldo FB, Alexander R, Wyatt RJ, et al.  Alternate-day prednisone therapy in children with IgA-associated nephritis. Am J Kidney Dis. 1989;13:55–60
  75. Waldo FB, Wyatt RJ, Kelly DR, et al.  Treatment of IgA nephropathy in children (Efficacy of alternate-day oral prednisone). Pediatr Nephrol. 1993;7:529–532
  76. Tanaka H, Waga S, Yokoyama M. Age-related histologic alterations after prednisolone therapy in children with IgA nephropathy. Tohoku J Exp Med. 1998;185:247–252
  77. Welch TR, Fryer C, Shely E, et al.  Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. J Pediatr. 1992;121:474–477
  78. Hogg RJ. A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with immunoglobulin A nephropathy. Scientific Planning Committee of the IgA Nephropathy Study Am J Kidney Dis. 1995;26:792–796
  79. Hogg RJ, Lee JL, Nardelli N, et al.  Multicenter, placebo-controlled trial of alternate-day prednisone (QOD-PRED) or daily omega-3 fatty acids (OM-3 FA) in children and young adults with IgA nephropathy (IgAN). Report from the Southwest Pediatric Nephrology Study Group. [Abstract] J Am Soc Nephrol. 2003;14:751A; (abstr)
  80. Andreoli SP, Bergstein JM. Treatment of severe IgA nephropathy in children. Pediatr Nephrol. 1989;3:248–253
  81. Yoshikawa N, Ito H, Sakai T, et al.  the Japanese Pediatric IgA Nephropathy Treatment Group   A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol. 1999;10:101–109
  82. Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol. 1999;3:147–152
  83. Xie Y, Nishi S, Ueno M. The efficacy of tonsillectomy on long-tern survival in patients with IgA nephropathy. Kidney Int. 2003;63:1861–1867
  84. Chan JC, Mahan JD, Trachtman H, et al.  Vitamin E therapy in IgA nephropathy (A double-blind, placebo-controlled study). Pediatr Nephrol. 2003;18:1015–1019
  85. D’Amico G. Natural history of idiopathic IgA nephropathy (Role of clinical and histological prognostic factors). Am J Kidney Dis. 2000;36:227–237
  86. Levy M, Broyer M, Arsan A, et al.  Anaphylactoid purpura nephritis in childhood (Natural history and immunopathology). Adv Nephrol. 1976;6:183–228
  87. Nakamoto Y, Yoshihiro A, Dohi K, et al.  Primary IgA glomerulonephritis and Schönlein-Henoch purpura nephritis (Clinicopathological and immunohistological characteristics). Q J Med. 1978;188:495–516
  88. Waldo FB. Is Henoch-Schönlein purpura the systemic form of IgA nephropathy?. Am J Kidney Dis. 1988;12:373–377
  89. Meadow SR, Scott DG. Berger disease (Henoch-Schönlein syndrome without the rash). J Pediatr. 1985;106:27–31
  90. Hughes FJ, Wolfish NM, McLaine PN. Henoch-Schönlein syndrome and IgA nephropathy (A case report suggesting a common pathogenesis). Pediatr Nephrol. 1988;2:389–392
  91. Kaneko K, Suzuki Y, Kiya K, et al.  A case report suggesting a common pathogenesis for IgA nephropathy and Henoch-Schönlein purpura. Pediatr Nephrol. 1994;8:750–751
  92. Watanabe T, Takada T, Kihara I, et al.  Three cases of Henoch-Schönlein purpura preceded by IgA nephropathy. Pediatr Nephrol. 1995;9:674
  93. Stewart M, Savage JM, Bell B, et al.  Long term renal prognosis of Henoch-Schönlein purpura in an unselected childhood population. Eur J Pediatr. 1988;147:113–115
  94. Nielsen HE. Epidemiology of Schönlein-Henoch purpura. Acta Paediatr Scand. 1988;77:125–131
  95. Calvino MC, Llorca J, Garcia-Porrua C, et al.  Henoch-Schönlein purpura in children from northwestern Spain. A 20-year epidemiologic and clinical study. Medicine. 2001;80:279–290
  96. Gardner-Medwin JM, Dolezalova P, Cummins C, et al.  Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360:1197–1202
  97. Abdel-Al YK, Hejazi Z, Majeed HA. Henoch Schönlein purpura in Arab children. Analysis of 52 cases. Trop Geogr Med. 1990;42:52–57
  98. al-Sheyyab M, el-Shanti H, Ajlouni S, et al.  Henoch-Schönlein purpura (Clinical experience and contemplations on a streptococcal association). J Trop Pediatr. 1996;42:200–2003
  99. Farley TA, Gillespie S, Rasoulpour M, et al.  Epidemiology of a cluster of Henoch-Schönlein purpura. Am J Dis Child. 1989;143:798–803
  100. Saulsbury FT. Henoch-Schönlein purpura in children (Report of 100 patients and review of the literature). Medicine. 1999;78:395–409
  101. Heberden W. Commentari di morborium historia et curatione. London: Payne; 1801; Reprinted as “Commentaries on the History and Cure of Diseases.” Birmingham, AL: The Classics of Medicine Library, Division of Gryphon Editions, Ltd; 1982:395–397
  102. Schonlein JL. Allgemeine und specielle Pathologie und therapie, vol 2. (3rd ed). Wurzburg: Herisau; 1837; 48
  103. Henoch E. Uber eine eigenthumliche form von purpura. Berl Klin Wochnschr. 1874;11:641–643
  104. Henoch E. Vorlesungen uber kinderkrankheiten. In:  Hirschward A editors. Vorlesuungen uber kinderkrankheiten. vol 10:Berlin: Aufl; 1899;p. 839
  105. Osler W. Visceral lesions of purpura and allied conditions. BMJ. 1914;1:517–525
  106. Mills JA, Michel BA, Bloch DA, et al.  The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum. 1990;33:1114–1121
  107. Michel BA, Hunder GG, Bloch DA, et al.  Hypersensitivity vasculitis and Henoch-Schönlein purpura (a comparison between the two disorders). J Rheumatol. 1992;19:721–728
  108. Evans DJ, Gwyn Williams D, Peters DK, et al.  Glomerular deposition of properdin in Henoch-Schönlein syndrome and idiopathic focal nephritis. BMJ. 1973;11:326–328
  109. Urizar RE, Michael A, Sisson S, et al.  Anaphylactoid purpura II. Immunofluorescent and electron microscopy studies of the glomerular lesions. Lab Invest. 1968;19:437–440
  110. Kobayashi O, Wada H, Okawa K, et al.  Schönlein-Henoch’s syndrome in children. Contrib Nephrol. 1977;40:250–254
  111. West CD, McAdams AJ, Welch TR. Glomerulonephritis in Henoch-Schönlein purpura without mesangial IgA deposition. Pediatr Nephrol. 1994;8:677–683
  112. Heaton JM, Turner DR, Cameron JS. Localization of glomerular “deposits” in Henoch-Schönlein nephritis. Histopathology. 1977;1:93–104
  113. Oliver TK, Barnett HL. Incidence and prognosis of nephritis associated with anaphylactoid (Schönlein-Henoch purpura in children. Am J Dis Child. 1955;90:544–547
  114. Wedgewood RJP, Klaus MH. Anaphylactoid purpura. A long term follow-up study with special reference to renal involvement. Pediatrics. 1955;16:196–206
  115. Allen DM, Diamond LK, Howell DA. Anaphylactoid purpura in children (Schönlein-Henoch syndrome). Am J Dis Child. 1960;99:833–854
  116. Koskimies O, Mir S, Rapola J, Vilska J. Henoch-Schönlein nephritis (Long-term prognosis of unselected patients). Arch Dis Child. 1981;56:482–484
  117. Zurowska AM, Wrzolkowa T, Uszycka-Karcz M. Henoch-Schönlein nephritis in children—A clinicopathological study. Int J Pediatr Nephrol. 1985;6:183–188
  118. Kaku Y, Nohara K, Honda S. Renal involvement in Henoch-Schönlein purpura (A multivariate analysis of prognostic features). Kidney Int. 1998;53:1755–1759
  119. Sano H, Izumida M, Shimizu H, et al.  Risk factors of renal involvement and significant proteinuria in Henoch-Schönlein purpura. Eur J Pediatr. 2002;161:196–201
  120. Meadow SR, Glasgow EF, White RH, et al.  Schönlein Henoch nephritis. Q J Med. 1972;41:241–258
  121. Hurley RM, Drummond KN. Anaphylactoid purpura nephritis (Clinico-pathological correlations). J Pediatr. 1972;81:904–911
  122. Counahan R, Winterborn MH, White RH, et al.  Prognosis of Henoch-Schönlein nephritis in children. BMJ. 1977;2:11–14
  123. Coppo R, Mazzucco G, Cagnoli L, et al.  Long-term prognosis of Henoch Schönlein nephritis in adults and children. Nephrol Dial Transplant. 1997;12:2277–2283
  124. Goodyer PR, de Chadarevian J-P, Kaplan BS. Acute poststreptococcal glomerulonephritis mimicking Henoch-Schönlein purpura. J Pediatr. 1978;93:412–415
  125. Onisawa S, Morishima N, Ichimura T. Concurrent poststreptococcal acute glomerulonephritis and Schönlein-Henoch purpura. Acta Paediatr Jpn. 1989;31:487–492
  126. Masuda M, Nakanishi N, Yoshizawa N, et al.  Group A streptococcal antigen in the glomeruli of children with Henoch-Schönlein nephritis. Am J Kidney Dis. 2003;41:366–370
  127. Bunchman TE, Mauer SM, Sibley RK, et al.  Anaphylactoid purpura (Characteristics of 16 patients who progressed to renal failure). Pediatr Nephrol. 1988;2:393–397
  128. Goldstein AR, White RHR, Akuse R, et al.  Long-term follow-up of childhood Henoch-Schönlein purpura nephritis. Lancet. 1992;339:280–282
  129. Scharer K, Krmar R, Querfeld U, et al.  Clinical outcome of Schönlein-Henoch purpura nephritis in children. Pediatr Nephrol. 1999;13:816–823
  130. Ronkainen J, Nututinen M, Koskimies O. The adult kidney 24 years after childhood Henoch-Schönlein purpura (A retrospective study). Lancet. 2002;360:666–670
  131. Algoet C, Proesmans W. Renal biopsy 2–9 years after Henoch Schönlein purpura. Pediatr Nephrol. 2003;18:471–473
  132. Pabunruang W, Treepongkaruna S, Tangnararatchakit K, et al.  Henoch-Schönlein purpura (Clinical manifestations and long-term outcomes in Thai children). J Med Assoc Thai. 2002;85(suppl 4):S1213–S1218
  133. Mestecky J, Tomana M, Crowley-Nowick PA, et al.  Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol. 1993;104:172–182
  134. Tomana M, Matousovic K, Julian BA, et al.  Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int. 1997;52:509–516
  135. Saulsbury FT. Alterations in the O-linked glycosylation of IgA1 in children with Henoch-Schönlein purpura. J Rheumatol. 1997;24:2246–2249
  136. Allen AC, Willis FR, Beattie TJ, et al.  Abnormal IgA glycosylation in Henoch-Schönlein purpura restricted to patients with clinical nephritis. Nephrol Dial Transplant. 1998;13:990–994
  137. Muller D, Greve D, Eggert P. Early tubular proteinuria and the development of nephritis in Henoch-Schönlein purpura. Pediatr Nephrol. 2000;15:85–89
  138. Namgoong MK, Lim BK, Kim JS. Eosinophilic cationic protein in Henoch-Schönlein purpura and in IgA nephropathy. Pediatr Nephrol. 1997;11:703–706
  139. Fujieda M, Oishi N, Naruse K, et al.  Soluble thrombomodulin and antibodies to bovine glomerular endothelial cells in patients with Henoch-Schönlein purpura. Arch Dis Child. 1998;78:240–244
  140. Besbas N, Saatci U, Ruacan S, et al.  The role of cytokines in Henoch Schönlein purpura. Scand J Rheumatol. 1997;26:456–460
  141. Muslu A, Islek I, Gok F, et al.  Endothelin levels in Henoch-Schönlein purpura. Pediatr Nephrol. 2002;17:920–925
  142. White RHR. Henoch-Schönlein purpura nephritis (a disease with significant late sequelae). Nephron. 1994;68:1–9
  143. Kumada K, Suzuki J, Kume K, et al.  Clinicopathological study of Henoch-Schönlein purpura nephritis with special reference to C3c deposits. Nippon Jinzo Gakkai Shi. 1996;38:259–268
  144. Amoroso A, Danek G, Vatta S, et al.  Polymorphisms in angiotensin-converting enzyme gene and severity of renal disease in Henoch-Schönlein patients. Italian Group of Renal Immunopathology Nephrol Dial Transplant. 1998;13:3184–3188
  145. Brodkiewicz A, Ciechanowicz A, Urbanska A, et al.  The I/D polymorphism of the ACE gene in children with Henoch-Schönlein purpura. Pol Merckuriusz Lex. 2000;8:236–238
  146. Dudley J, Afifi E, Gardner A, et al.  Polymorphism of the ACE gene in Henoch-Schönlein purpura nephritis. Pediatr Nephrol. 2000;14:218–220
  147. Yoshioka T, Xu YX, Yoshida H, et al.  Deletion polymorphism of the angiotensin converting enzyme gene predicts persistent proteinuria in Henoch-Schönlein purpura nephritis. Arch Dis Child. 1998;79:394–399
  148. Amoli MM, Thomson W, Hajeer AH, et al.  Interleukin 1 receptor antagonist gene polymorphism is associated with severe renal involvement and renal sequelae in Henoch-Schönlein purpura. J Rheumatol. 2002;29:1404–1407
  149. Ault BH, Stapleton FB, Rivas ML, et al.  Association of Henoch-Schönlein purpura glomerulonephritis and C4B deficiency. J Pediatr. 1990;117:753–755
  150. Buchanec J, Galanda V, Belakova S, et al.  Incidence of renal complications in Schönlein-Henoch purpura syndrome in dependence on an early administration of steroids. Int Urol Nephrol. 1988;20:409–412
  151. Mollica F, Li Volti S, Garozzo R, et al.  Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura. Eur J Pediatr. 1992;151:140–144
  152. Saulsbury FT. Corticosteroid therapy does not prevent nephritis in Henoch-Schönlein purpura. Pediatr Nephrol. 1993;7:69–71
  153. Oner A, Tinaztepe K, Erdogan O. The effect of triple therapy on rapidly progressive type of Henoch-Schönlein nephritis. Pediatr Nephrol. 1995;9:6–10
  154. Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis. Pediatr Nephrol. 1998;12:238–243
  155. Bergstein J, Leiser J, Andreoli SP. Response of crescentic Henoch-Schönlein purpura nephritis to corticosteroid and azathioprine therapy. Clin Nephrol. 1988;49:9–14
  156. Iijima K, Ito-Kariya S, Nakamura H, et al.  Multiple combined therapy for severe Henoch-Schönlein nephritis in children. Pediatr Nephrol. 1998;12:244–248
  157. Hattori M, Ito K, Konomoto T, et al.  Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schönlein purpura nephritis in children. Am J Kid Dis. 1999;33:427–433
  158. Tanaka H, Suzuki K, Nakahata T, Ito E, Waga S. Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis. Pediatr Nephrol. 2003;18:347–350
  159. Foster BJ, Bernard C, Drummond KN, et al.  Effective therapy for severe Henoch-Schönlein purpura nephritis with prednisone and azathioprine (A clinical and histopathologic study). J Pediatr. 2000;136:370–375
  160. Watanabe T, Takahashi S, Nakajo S, et al.  Pathological improvement of IgA nephropathy and Henoch-Schönlein purpura nephritis with urokinase therapy. Acta Paediatr Jpn. 1996;38:622–628
  161. Kawasaki Y, Suzuki J, Nozawa R, et al.  Efficacy of methylprednisolone and urokinase pulse therapy for severe Henoch-Schönlein nephritis. Pediatrics. 2003;111:785–789

PII: S0270-9295(04)00009-9

doi: 10.1016/j.semnephrol.2004.01.007

Seminars in Nephrology
Volume 24, Issue 3 , Pages 269-286 , May 2004

Article Tools